Pharmaceutical
Health
Therapy

Corcept Therapeutics

1,109

$17.18
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.09 (+0.53%) Today
$0.00 (0.00%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell CORT and other stocks, options, ETFs, and crypto commission-free!

About CORT

Corcept Therapeutics Incorporated Common Stock, also called Corcept Therapeutics, is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Read More Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

CEO
Joseph K. Belanoff
Employees
206
Headquarters
Menlo Park, California
Founded
1998
Market Cap
1.97B
Price-Earnings Ratio
19.70
Dividend Yield
—
Average Volume
1.29M
High Today
$17.49
Low Today
$16.84
Open Price
$17.31
Volume
806.06K
52 Week High
$18.53
52 Week Low
$9.70

Collections

Pharmaceutical
Health
Therapy
Technology

CORT News

ReutersJun 30

BRIEF-Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients

June 30 (Reuters) - Corcept Therapeutics Inc: * CORCEPT THERAPEUTICS INITIATES PHASE 3 TRIAL OF RELACORILANT PLUS NAB-PACLITAXEL IN PATIENTS WITH METASTATIC PA
0

CORT Earnings

$0.00
$0.11
$0.23
$0.34
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Estimated
— per share
Actual
Expected Jul 30, After Hours

You May Also Like

IIF
TWNKW
XMPT
TTEC
FOSL
GEVO
EFF
WAL
DCPH
UTRN
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.

Buy CORT

Market Price$17.18
Commissions$0.00
Estimated Cost
$0.00
Sign up for a Robinhood Account to buy or sell CORT stock and options commission-free.
LearnBlogCareersHelpLog InSign Up